FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1773-1775 April 26, 2007 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The DAD Study Group PubMed Citation

Treatment with potent antiretroviral therapy has transformed human immunodeficiency virus (HIV) infection from a rapidly fatal disease into a chronic illness that some patients can live with for more than two decades. However, shortly after antiretroviral therapy was introduced, there were several reports of acute myocardial infarction and premature atherosclerotic vascular disease among young patients receiving such treatment.¹ Attention quickly focused on the protease inhibitors, with speculation that lipodystrophy and its associated metabolic disorders, including hyperlipidemia and insulin resistance, were increasing the cardiovascular risk.

These findings were alarming, and a flurry of research reports and editorials created a sense of . . . [Full Text of this Article]

Source Information

From the University of Wisconsin School of Medicine and Public Health, Madison.

Related Letters:

Antiretroviral Drugs and the Risk of Myocardial Infarction
Kaplan R. C., Tien P. C., Lazar J., Zangerle R., Sarcletti M., Pollack T. M., Rind D. M., Sabin C., Friis-Møller N., Lundgren J. D., the Writing Committee of the DAD Study Group , Stein J. H.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:715-717, Aug 16, 2007. Correspondence

This article has been cited by other articles:

• Schambelan, M., Wilson, P. W.F., Yarasheski, K. E., Cade, W. T., Davila-Roman, V. G., D'Agostino, R. B. Sr, Helmy, T. A., Law, M., Mondy, K. E., Nachman, S., Peterson, L. R., Worm, S. W., for Working Group 5, (2008). Development of Appropriate Coronary Heart Disease Risk Prediction Models in HIV-Infected Patients. Circulation 118: e48-e53 [Full Text]  
• Stein, J. H., Hadigan, C. M., Brown, T. T., Chadwick, E., Feinberg, J., Friis-Moller, N., Ganesan, A., Glesby, M. J., Hardy, D., Kaplan, R. C., Kim, P., Lo, J., Martinez, E., Sosman, J. M., for Working Group 6, (2008). Prevention Strategies for Cardiovascular Disease in HIV-Infected Patients. Circulation 118: e54-e60 [Full Text]  
• Lindsay, A. (2007). JournalScan. Heart 93: 1159-1160 [Full Text]  
• Kaplan, R. C., Tien, P. C., Lazar, J., Zangerle, R., Sarcletti, M., Pollack, T. M., Rind, D. M., Sabin, C., Friis-Moller, N., Lundgren, J. D., the Writing Committee of the DAD Study Group, , Stein, J. H. (2007). Antiretroviral drugs and the risk of myocardial infarction.. NEJM 357: 715-716 [Full Text]  
• Glick, M. (2007). The health questionnaire: A continually changing component of practice. Journal of the American Dental Association 138: 932-934 [Full Text]  
• (2007). Long-Term ART and Risk for Myocardial Infarction. JWatch Infect. Diseases 2007: 1-1 [Full Text]  
• (2007). Antiretroviral Therapy and Cardiovascular Disease. AIDS Clin Care 2007: 1-1 [Full Text]